Prostate Cancer Metastatic
Oncology·MeSH: Prostatic Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
9 drugs in development·5 companies·14 clinical trials
Drug Pipeline by Phase
Phase 3(4)
Phase 2(1)
| Drug | Company |
|---|---|
| Enhertu | KYNTRA BIO INC. (KYNB) |
Phase 1(1)
| Drug | Company |
|---|---|
| Bavdegalutamide | ARVINAS, INC. (ARVN) |
Phase 1/Phase 2(3)
Compare drugs
Frequently asked questions
How many drugs are in development for Prostate Cancer Metastatic?
BioSniper tracks 9 drugs in development for Prostate Cancer Metastatic across 5 companies.
How many clinical trials target Prostate Cancer Metastatic?
There are 14 clinical trials targeting Prostate Cancer Metastatic tracked by BioSniper.
What is the prevalence of Prostate Cancer Metastatic?
The estimated prevalence of Prostate Cancer Metastatic is approximately 256.0 per 100,000 population.
Deep-dive into Prostate Cancer Metastatic
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis